267 related articles for article (PubMed ID: 32053005)
1. Inhibiting DosRST as a new approach to tuberculosis therapy.
Zheng H; Abramovitch RB
Future Med Chem; 2020 Mar; 12(5):457-467. PubMed ID: 32053005
[TBL] [Abstract][Full Text] [Related]
2. Inhibiting
Zheng H; Williams JT; Aleiwi B; Ellsworth E; Abramovitch RB
ACS Chem Biol; 2020 Jan; 15(1):52-62. PubMed ID: 31556993
[No Abstract] [Full Text] [Related]
3. Inhibitors of Mycobacterium tuberculosis DosRST signaling and persistence.
Zheng H; Colvin CJ; Johnson BK; Kirchhoff PD; Wilson M; Jorgensen-Muga K; Larsen SD; Abramovitch RB
Nat Chem Biol; 2017 Feb; 13(2):218-225. PubMed ID: 27992879
[TBL] [Abstract][Full Text] [Related]
4. Editorial: Current status and perspective on drug targets in tubercle bacilli and drug design of antituberculous agents based on structure-activity relationship.
Tomioka H
Curr Pharm Des; 2014; 20(27):4305-6. PubMed ID: 24245755
[TBL] [Abstract][Full Text] [Related]
5. Mycobacterium tuberculosis Low Molecular Weight Phosphatases (MPtpA and MPtpB): From Biological Insight to Inhibitors.
Fanzani L; Porta F; Meneghetti F; Villa S; Gelain A; Lucarelli AP; Parisini E
Curr Med Chem; 2015; 22(27):3110-32. PubMed ID: 26264920
[TBL] [Abstract][Full Text] [Related]
6. Design, synthesis and investigation on the structure-activity relationships of N-substituted 2-aminothiazole derivatives as antitubercular agents.
Pieroni M; Wan B; Cho S; Franzblau SG; Costantino G
Eur J Med Chem; 2014 Jan; 72():26-34. PubMed ID: 24333612
[TBL] [Abstract][Full Text] [Related]
7. Selective killing of nonreplicating mycobacteria.
Bryk R; Gold B; Venugopal A; Singh J; Samy R; Pupek K; Cao H; Popescu C; Gurney M; Hotha S; Cherian J; Rhee K; Ly L; Converse PJ; Ehrt S; Vandal O; Jiang X; Schneider J; Lin G; Nathan C
Cell Host Microbe; 2008 Mar; 3(3):137-45. PubMed ID: 18329613
[TBL] [Abstract][Full Text] [Related]
8. [Development of antituberculous drugs: current status and future prospects].
Tomioka H; Namba K
Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
[TBL] [Abstract][Full Text] [Related]
9. Deletion of
Khan MZ; Nandicoori VK
Antimicrob Agents Chemother; 2021 Mar; 65(4):. PubMed ID: 33468473
[TBL] [Abstract][Full Text] [Related]
10. A Novel Small-Molecule Inhibitor of the
Sukheja P; Kumar P; Mittal N; Li SG; Singleton E; Russo R; Perryman AL; Shrestha R; Awasthi D; Husain S; Soteropoulos P; Brukh R; Connell N; Freundlich JS; Alland D
mBio; 2017 Feb; 8(1):. PubMed ID: 28196957
[TBL] [Abstract][Full Text] [Related]
11.
Sawicki R; Ginalska G
Future Med Chem; 2019 Aug; 11(16):2193-2203. PubMed ID: 31538522
[TBL] [Abstract][Full Text] [Related]
12. Extreme Drug Tolerance of Mycobacterium tuberculosis in Caseum.
Sarathy JP; Via LE; Weiner D; Blanc L; Boshoff H; Eugenin EA; Barry CE; Dartois VA
Antimicrob Agents Chemother; 2018 Feb; 62(2):. PubMed ID: 29203492
[TBL] [Abstract][Full Text] [Related]
13. The relevance of persisters in tuberculosis drug discovery.
Mandal S; Njikan S; Kumar A; Early JV; Parish T
Microbiology (Reading); 2019 May; 165(5):492-499. PubMed ID: 30775961
[TBL] [Abstract][Full Text] [Related]
14. Harnessing Biological Insight to Accelerate Tuberculosis Drug Discovery.
de Wet TJ; Warner DF; Mizrahi V
Acc Chem Res; 2019 Aug; 52(8):2340-2348. PubMed ID: 31361123
[TBL] [Abstract][Full Text] [Related]
15. Derivatives of 3-isoxazolecarboxylic acid esters: a potent and selective compound class against replicating and nonreplicating Mycobacterium tuberculosis.
Lilienkampf A; Pieroni M; Franzblau SG; Bishai WR; Kozikowski AP
Curr Top Med Chem; 2012; 12(7):729-34. PubMed ID: 22283815
[TBL] [Abstract][Full Text] [Related]
16. [Recent progress in mycobacteriology].
Okada M; Kobayashi K
Kekkaku; 2007 Oct; 82(10):783-99. PubMed ID: 18018602
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of NarL of Mycobacterium Tuberculosis: an in silico approach.
Shivakumar KV; Karunakar P; Chatterjee J
Interdiscip Sci; 2014 Dec; 6(4):292-9. PubMed ID: 25240609
[TBL] [Abstract][Full Text] [Related]
18. Discovery of novel lysine ɛ-aminotransferase inhibitors: An intriguing potential target for latent tuberculosis.
Devi PB; Sridevi JP; Kakan SS; Saxena S; Jeankumar VU; Soni V; Anantaraju HS; Yogeeswari P; Sriram D
Tuberculosis (Edinb); 2015 Dec; 95(6):786-794. PubMed ID: 26299907
[TBL] [Abstract][Full Text] [Related]
19. Current Advances in Antitubercular Drug Discovery: Potent Prototypes and New Targets.
Dos Santos Fernandes GF; Jornada DH; de Souza PC; Chin CM; Pavan FR; Dos Santos JL
Curr Med Chem; 2015; 22(27):3133-61. PubMed ID: 26282941
[TBL] [Abstract][Full Text] [Related]
20. Drug targets in dormant Mycobacterium tuberculosis: can the conquest against tuberculosis become a reality?
Gupta VK; Kumar MM; Singh D; Bisht D; Sharma S
Infect Dis (Lond); 2018 Feb; 50(2):81-94. PubMed ID: 28933243
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
